tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Scorpion Stings D065008 1 associated lipids
Drug-Related Side Effects and Adverse Reactions D064420 3 associated lipids
Retrognathia D063173 1 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Candidiasis, Invasive D058365 2 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Central Serous Chorioretinopathy D056833 1 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Netherton Syndrome D056770 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Invasive Pulmonary Aspergillosis D055744 1 associated lipids
Keratosis, Actinic D055623 3 associated lipids
Multiple Pulmonary Nodules D055613 2 associated lipids
Pancreatitis, Graft D055589 1 associated lipids
Failed Back Surgery Syndrome D055111 3 associated lipids
Primary Graft Dysfunction D055031 1 associated lipids
Idiopathic Interstitial Pneumonias D054988 1 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Precursor Cell Lymphoblastic Leukemia-Lymphoma D054198 10 associated lipids
Posterior Leukoencephalopathy Syndrome D054038 1 associated lipids
Dysuria D053159 1 associated lipids
Nocturia D053158 1 associated lipids
Delayed Graft Function D051799 2 associated lipids
Renal Insufficiency D051437 8 associated lipids
Lymphohistiocytosis, Hemophagocytic D051359 1 associated lipids
Granulomatosis, Orofacial D051261 2 associated lipids
Atherosclerosis D050197 85 associated lipids
Dyslipidemias D050171 7 associated lipids
Diabetes Complications D048909 4 associated lipids
Hepatic Insufficiency D048550 1 associated lipids
Colitis, Collagenous D046729 1 associated lipids
Protoporphyria, Erythropoietic D046351 1 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Ileus D045823 3 associated lipids
Intestinal Volvulus D045822 1 associated lipids
Cholecystolithiasis D041761 2 associated lipids
Mastocytosis, Cutaneous D034701 1 associated lipids
Hypoalbuminemia D034141 1 associated lipids
Hyperuricemia D033461 4 associated lipids
Papillomavirus Infections D030361 4 associated lipids
Denys-Drash Syndrome D030321 1 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Polyomavirus Infections D027601 1 associated lipids
Coronary Stenosis D023921 6 associated lipids
Lacerations D022125 1 associated lipids
Brachial Plexus Neuritis D020968 2 associated lipids
Neuroaspergillosis D020953 2 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Central Nervous System Viral Diseases D020805 1 associated lipids
Intracranial Thrombosis D020767 2 associated lipids
Parkinsonian Disorders D020734 20 associated lipids
Nervous System Autoimmune Disease, Experimental D020721 3 associated lipids
Stroke D020521 32 associated lipids
Brain Infarction D020520 17 associated lipids
Peroneal Neuropathies D020427 1 associated lipids
Sciatic Neuropathy D020426 13 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Paraneoplastic Syndromes, Nervous System D020361 1 associated lipids
Hypertensive Encephalopathy D020343 1 associated lipids
Migraine with Aura D020325 1 associated lipids
Autoimmune Diseases of the Nervous System D020274 1 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Optic Nerve Injuries D020221 4 associated lipids
Facial Nerve Injuries D020220 1 associated lipids
Trauma, Nervous System D020196 2 associated lipids
Nocturnal Myoclonus Syndrome D020189 1 associated lipids
Sleep Apnea, Central D020182 1 associated lipids
Citrullinemia D020159 1 associated lipids
Hepatopulmonary Syndrome D020065 1 associated lipids
Epstein-Barr Virus Infections D020031 3 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Miller Fisher Syndrome D019846 1 associated lipids
Hepatitis C, Chronic D019698 12 associated lipids
Hepatitis B, Chronic D019694 4 associated lipids
Hepatitis, Autoimmune D019693 1 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Intracranial Hypertension D019586 4 associated lipids
Dermatitis, Perioral D019557 4 associated lipids
Pouchitis D019449 3 associated lipids
Endotoxemia D019446 27 associated lipids
Oral Ulcer D019226 1 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Fasciitis, Necrotizing D019115 1 associated lipids
Postoperative Hemorrhage D019106 7 associated lipids
Multiple Endocrine Neoplasia Type 2a D018813 1 associated lipids
Anemia, Iron-Deficiency D018798 6 associated lipids
Encephalitis, Viral D018792 3 associated lipids
Hypoplastic Left Heart Syndrome D018636 1 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Lichen Sclerosus et Atrophicus D018459 2 associated lipids
Vasculitis, Leukocytoclastic, Cutaneous D018366 5 associated lipids
Hutchinson's Melanotic Freckle D018327 2 associated lipids
Angiofibroma D018322 2 associated lipids
Cervical Intraepithelial Neoplasia D018290 1 associated lipids
Seminoma D018239 2 associated lipids
Smooth Muscle Tumor D018235 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Ito T et al. The mechanism of tolerance induced by a perioperative injection of bone marrow cells and a brief course of FK 506. 1991 Transplant. Proc. pmid:1703716
The discovery of FK-506 and U.S. development. 1991 Nephrol News Issues pmid:1720512
Zheng B et al. Effects of the new and highly active immunosuppressant, rapamycin, on lymphoid tissues and cells in vivo. 1991 Transplant. Proc. pmid:1703717
Farghali H et al. Effect of FK 506 chronic administration on bromosulphthalein hepatic excretion in rats. 1991 Transplant. Proc. pmid:1721283
Zeevi A et al. Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK 506, cyclosporine, and rapamycin. 1991 Transplant. Proc. pmid:1721315
Nakamura K et al. The lymphocytotoxic crossmatch in liver transplantation: a clinicopathologic analysis. 1991 Transplant. Proc. pmid:1721346
Jain AB et al. Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant. 1991 Transplant. Proc. pmid:1721347
Wagner K et al. Effect of FK 506 on excretion of urinary enzymes in rats. 1991 Transplant. Proc. pmid:1721379
Warty V et al. Distribution of FK 506 in plasma lipoproteins in transplant patients. 1991 Transplant. Proc. pmid:1703363
Ricordi C et al. Human islet allotransplantation under FK 506. 1991 Transplant. Proc. pmid:1721410
Katayama Y et al. Immunosuppressive effects of FK 506 in rat lung transplantation. 1991 Transplant. Proc. pmid:1721441
Yokomise H et al. Immunosuppressive effects of FK 506 in canine lung transplantation. 1991 Transplant. Proc. pmid:1721442
Albers MW et al. Relationship of FKBP to PKCI-2. 1991 Nature pmid:1710782
Stevens C et al. The effects of immunosuppressive agents on in vitro production of human immunoglobulins. 1991 Transplantation pmid:1710843
Sakai K et al. The effect of a new immunosuppressive agent, FK-506, on xenogeneic neural transplantation in rodents. 1991 Brain Res. pmid:1723023
Forrest MJ et al. FK-506 and cyclosporin A: selective inhibition of calcium ionophore-induced polymorphonuclear leukocyte degranulation. 1991 Biochem. Pharmacol. pmid:1716098
Epand RF and Epand RM The new potent immunosuppressant FK-506 reverses multidrug resistance in Chinese hamster ovary cells. 1991 Anticancer Drug Des. pmid:1714737
Gailliot FP et al. Fluidized bed adsorption for whole broth extraction. 1990 Sep-Oct Biotechnol. Prog. pmid:1366874
Naouri A and Tissot E [Indications for liver transplantation in adults]. 1990 Jun-Jul J Chir (Paris) pmid:1698800
MacLeod AM and Thomson AW [FK-506. A new immunosuppressive drug]. 1990 Jul-Sep Medicina (Firenze) pmid:1706817
Wasik M et al. Effect of FK-506 and cyclosporine on human T and B lymphoproliferative responses. 1990 Jul-Aug Immunopharmacology pmid:1699911
Li PK et al. The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506. 1990 Adverse Drug React Acute Poisoning Rev pmid:1703724
McCauley J et al. The effects of FK 506 on renal function after liver transplantation. 1990 Transplant. Proc. pmid:1689887
Kang Y et al. Acute hemodynamic effects of FK 506 during and after orthotopic liver transplantation. 1990 Transplant. Proc. pmid:1689889
Jain AB et al. FK 506 dosage in human organ transplantation. 1990 Transplant. Proc. pmid:1689890
Demetris AJ et al. Pathologic observations in human allograft recipients treated with FK 506. 1990 Transplant. Proc. pmid:1689891
Shapiro R et al. The side effects of FK 506 in humans. 1990 Transplant. Proc. pmid:1689892
Van Thiel DH et al. Gastrointestinal and metabolic problems associated with immunosuppression with either CyA or FK 506 in liver transplantation. 1990 Transplant. Proc. pmid:1689893
Mieles L et al. Oral glucose tolerance test in liver recipients treated with FK 506. 1990 Transplant. Proc. pmid:1689894
Alessiani M et al. Infections with FK 506 immunosuppression: preliminary results with primary therapy. 1990 Transplant. Proc. pmid:1689895
Metcalfe SM and Richards FM Cyclosporine, FK506, and rapamycin. Some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. 1990 Transplantation pmid:1691537
Morimoto T et al. Pancreaticoduodenal allotransplantation with FK 506 in the dog. 1990 Transplant. Proc. pmid:1691550
Yasunami Y et al. Characterization of the immunosuppressive activity of FK 506 in rat islet allografts. 1990 Transplant. Proc. pmid:1691557
Thomson AW FK-506 enters the clinic. 1990 Immunol. Today pmid:1692221
Saitoh Y et al. Morphological rejection phases and cytotoxic activity in peripheral blood lymphocytes in canine lung allo-transplantation. 1990 Jpn J Surg pmid:1692892
Rosen MK et al. Inhibition of FKBP rotamase activity by immunosuppressant FK506: twisted amide surrogate. 1990 Science pmid:1693013
Thomas FT et al. Comparative efficacy of immunosuppressive drugs in xenografting. 1990 Transplant. Proc. pmid:1693452
Harrison RK and Stein RL Substrate specificities of the peptidyl prolyl cis-trans isomerase activities of cyclophilin and FK-506 binding protein: evidence for the existence of a family of distinct enzymes. 1990 Biochemistry pmid:1693856
Starzl TE et al. Kidney transplantation under FK 506. 1990 JAMA pmid:1693970
Todo S et al. Liver, kidney, and thoracic organ transplantation under FK 506. 1990 Ann. Surg. pmid:1697743
Sakr MF et al. FK 506 ameliorates the hepatic injury associated with ischemia. 1990 Life Sci. pmid:1698241
Kurasawa K et al. The immunosuppressant FK-506 prevents progression of diabetes in nonobese diabetic mice. 1990 Clin. Immunol. Immunopathol. pmid:1698584
Miyagawa J et al. Preventive effect of a new immunosuppressant FK-506 on insulitis and diabetes in non-obese diabetic mice. 1990 Diabetologia pmid:1698679
Lagodzinski Z et al. Effect of FK506 and cyclosporine on primary and secondary skin allograft survival in mice. 1990 Immunology pmid:1698713
Wilkinson PC and Watson EA FK506 and pertussis toxin distinguish growth-induced locomotor activation from attractant-stimulated locomotion in human blood lymphocytes. 1990 Immunology pmid:1702750
Metcalfe S and Milner J Phosphatases PP1 and PP2A act after the G0/G1 interface in lymphocyte activation. 1990 Immunol. Lett. pmid:1702753
Takada K et al. Determination of a novel potent immunosuppressant (FK-506) in rat serum and lymph by high-performance liquid chromatography with chemiluminescence detection. 1990 J. Chromatogr. pmid:1703552
Woo J et al. Antigen presentation and HLA-DR expression by FK-506-treated human monocytes. 1990 Immunology pmid:1703987
Fung JJ et al. Overview of FK506 in transplantation. 1990 Clin Transpl pmid:1715740
Pugh-Humphreys RG et al. The influence of FK-506 on the thymus: an immunophenotypic and structural analysis. 1990 Immunology pmid:1696242